Noncovalent PEGylation: Different effects of dansyl-, l-tryptophan-, phenylbutylamino-, benzyl- and cholesteryl-PEGs on the aggregation of salmon calcitonin and lysozyme

Journal of Pharmaceutical Sciences

Volumn 101, Issue 6, 2012, Pages 1995-2008

  Mueller, Claudia ^a,b   Capelle, Martinus A H ^a   Seyrek, Emek ^a   Martel, Sophie ^a   Carrupt, Pierre Alain ^a   Arvinte, Tudor ^a   Borchard, Gerrit ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Parc d'Affaires International   (France)

Author keywords

Noncovalent PEGylation; Protein aggregation; Protein delivery; Protein formulation; Proteins; Salmon calcitonin; Stability

Indexed keywords

CHOLESTEROL; CHOLESTERYL MPEG; DANSYL AMIDE; DANSYL MPEG; EXCIPIENT; LYSOZYME; MACROGOL; PHENYLBUTYLAMINE; POLYMER; SALCATONIN; TRYPTOPHAN; TRYPTOPHAN MPEG; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN STABILITY; PUBLICATION;

EID: 84859750364     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23110     Document Type: Article

References (36)

1. Leader B, Baca QJ, Golan DE. 2008. Protein therapeutics: A summary and pharmacological classification. Nat Rev 7:21-39.
2. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1-30.
3. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98:2909-2934.
4. Shire SJ. 2009. Formulation and manufacturability of biologics. Curr Opin Biotechnol 20:708-714.
5. Philo JS, Arakawa T. 2009. Mechanisms of protein aggregation. Curr Pharm Biotechnol 10:348-351.
6. Wang W, Nema S, Teagarden D. 2010. Protein aggregation pathways and influencing factors. Int J Pharm 390:89-99.
7. Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh M, Zhou J, Petti X, Janjua A, Mendez M, Liu J, Longley C, Zhihua Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. 2006. Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-pegylation. Bioconjug Chem 17:618-630.
8. Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Müller F, Senn H. 2005. Structural and biophysical characterization of the 40 kDa PEG-interferon-α2a and its individual positional isomers. Bioconjug Chem 16:504-517.
9. Rajan RS, Li T, Aras M, Sloey C, Sutherland W, Arai H, Briddell R, Kinstler O, Lueras AM, Zhang Y, Yeghnazar H, Treuheit M, Brems DN. 2006. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci 15:1063-1075.
10. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277.
11. Graham ML. 2003. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 55:1293-1302.
12. Katre NV. 1993. The conjugation of proteins with polyethylene glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential. Adv Drug Deliv Rev 10:91-114.
13. Veronese FM, Pasut G. 2009. PEGylation: Posttranslational bioengineering of protein biotherapeutics. Drug Discov Today Technol 5:e57-e64.
14. Borchard G, Mueller C, Capelle MAH, Arvinte T. 2009. Stabilized protein formulations and use thereof. Patent US61257054.
15. Mueller C, Capelle MAH, Seyrek E, Arvinte T, Borchard G. 2011. Tryptophan-mPEGs: Novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation. Eur J Pharm Biopharm 79:646-657.
16. Mueller C, Capelle, MAH, Seyrek E, Arvinte T, Borchard G. 2011. Non-covalent PEGylation as a new means against aggregation of salmon calcitonin. J Pharm Sci 100:1648-1662.
17. Veronese F. 1994. Biologically active drug polymer derivatives and method for preparing same. Patent US005286637.
18. Voigt R. 2000. Emulsionen. In Pharmazeutische technologie: Für studium und beruf; Fahr A, Ed. 9th ed. Stuttgart, Germany: Deutscher Apotheker Verlag Stuttgart, pp 349.
19. Trimaille T, Mondon K, Gurny R, Moller M. 2006. Novel polymeric micelles for hydrophobic drug delivery based on biodegradable poly(hexyl-substituted lactides). Int J Pharm 319:147-154.
20. Capelle MA, Gurny R, Arvinte T. 2009. A high throughput protein formulation platform: Case study of salmon calcitonin. Pharm Res 26:118-128.
21. Homchaudhuri L, Kumar S, Swaminathan R. 2006. Slow aggregation of lysozyme in alkaline pH monitored in real time employing the fluorescence anisotropy of covalently labelled dansyl probe. FEBS Lett 580:2097-2101.
22. Kumar S, Ravi VK, Swaminathan R. 2009. Suppression of lysozyme aggregation at alkaline pH by tri-N-acetylchitotriose. Biochim Biophys Acta 1794:913-920. doi:10.1016/j.bbapap.2009.01.009.
23. Dust JM, Fang, Z, Harris JM. 1990. Proton NMR characterization of poly(ethylene glycols) and derivatives. Macromolecules 23:3742-3746.
24. Goyal MK, Roy I, Banerjee UC, Sharma VK, Bansal AK. 2009. Role of benzyl alcohol in the prevention of heat-induced aggregation and inactivation of hen egg white lysozyme. Eur J Pharm Biopharm 71:367-376.
25. Lam XM, Patapoff TW, Nguyen TH. 1997. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm Res 14:725-729.
26. Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. 2005. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci 94:382-396.
27. Roy S, Katayama D, Dong A, Kerwin BA, Randolph TW, Carpenter JF. 2006. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry 45:3898-3911.
28. Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF. 2006. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95:1480-1497.
29. Tobler SA, Holmes BW, Cromwell ME, Fernandez EJ. 2004. Benzyl alcohol-induced destabilization of interferon-gamma: A study by hydrogen-deuterium isotope exchange. J Pharm Sci 93:1605-1617.
30. Arvinte T, Cudd A, Drake AF. 1993. The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 268:6415-6422.
31. Maier R, Brugger M, Bruckner H, Kamber B, Riniker B, Rittel W. 1977. Analogues of human calcitonin. Acta Endocrinol 85:102-108.
32. Seyferth S, Lee G. 2003. Structural studies of EDTA-induced fibrillation of salmon calcitonin. Pharm Res 20:73-80.
33. van Dijkhuizen-Radersma R, Nicolas HM, van de Weert M, Blom M, de Groot K, Bezemer JM. 2002. Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems. Int J Pharm 248:229-237.
34. Baudyš M, Mix D, Kim SW. 1996. Stabilization and intestinal absorption of human calcitonin. J Control Release 39:145-151.
35. Griffin W. 1954. Calculations of HLB values of nonionic surfactants. J Soc Cosmet Chem 5:249-256.
36. Kumar S, Ravi VK, Swaminathan R. 2008. How do surfactants and DTT affect the size, dynamics, activity and growth of soluble lysozyme aggregates? Biochem J 415:275-288.